Table 2.
Primary outcome by group
| Outcome | Pregnant cases (n=38), n/N (%) | Nonpregnant controls (n=94), n/N (%) | Adjusted P value | Adjusted OR (95% CI) |
|---|---|---|---|---|
| Composite morbiditya | 13/38 (34.2) | 14/94 (14.9) | .03 | 4.6 (1.2–18.2) |
| High-flow nasal cannula | 8/38 (21.1) | 6/94 (6.4) | –– | –– |
| BiPAP or CPAP | 3/38 (7.9) | 4/94 (4.3) | –– | –– |
| Intubation or mechanical ventilation | 10/38 (26.3) | 10/94 (10.6) | .22 | 3.3 (0.5–21.1) |
| ECMO | 0/38 (0.0) | 0/94 (0.0) | –– | –– |
| Death | 0/38 (0.0) | 3/94 (3.2) | –– | –– |
BiPAP, bilevel positive airway pressure; CI, confidence interval; CPAP, continuous positive airway pressure; ECMO, extracorporeal membrane oxygenation; OR, odds ratio.
DeBolt et al. Severe and critical COVID-19 in pregnant vs nonpregnant controls. Am J Obstet Gynecol 2021.
a
Composite morbidity includes need for high-flow nasal cannula supplementation, noninvasive positive pressure ventilation, intubation or mechanical ventilation, extracorporeal membrane oxygenation, and death.